A Phase 3 interventional study of dimethyl fumarate and Interferon β-1a in Relapsing-Remitting Multiple Sclerosis, sponsored by Biogen. Completed at 62 sites in 18 countries. Open to participants aged 10 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-05-19.
Sponsored by Biogen · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing Dimethyl Fumarate in Multiple Sclerosis, Relapsing-Remitting — none open to participants now, none under way, none of them phase 3. Dimethyl Fumarate · Multiple Sclerosis, Relapsing-Remitting.
Among the 22 studies testing Dimethyl Fumarate in Multiple Sclerosis, Relapsing-Remitting, this one is the 9th largest by enrollment, is one of 3 that started in 2014, is one of 10 in phase 3, and was the 10th registered.
618 studies on the registry are indexed under Multiple Sclerosis, Relapsing-Remitting; 83 are open to participants now.
Browse Multiple Sclerosis, Relapsing-Remitting studies →None of the 22 studies testing Dimethyl Fumarate in Multiple Sclerosis, Relapsing-Remitting is open now. The open studies under Multiple Sclerosis, Relapsing-Remitting, anywhere →
Dimethyl Fumarate: first FDA approval 2013 (TECFIDERA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 61 Multiple Sclerosis, Relapsing-Remitting studies recruiting now, 11 (18%) set no upper age limit and 44 (72%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.
This study: 10 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 3 started in 2014.
This study's enrollment of 156 is above the median of 66 across 437 interventional studies indexed under Multiple Sclerosis, Relapsing-Remitting.
Median enrollment 61 across the 22 interventional studies. Of the 18 that completed or were terminated, 10 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 22 have an industry lead sponsor. The 5 most frequent:
Biogen is the lead sponsor of 512 studies on the registry; 25 are open to participants now.
Of its 100 completed or terminated interventional studies of FDA-regulated products, 50 (50%) have results posted.
78 studies in Multiple Sclerosis, Relapsing-Remitting by Biogen: none open now, 1 under way, 1 of them phase 3. Of 72 finished, 31 (43%) have results posted.
Among the 78 studies in Multiple Sclerosis, Relapsing-Remitting by Biogen, this one is the 29th largest by enrollment of the 59 interventional ones that give a count, is one of 6 that started in 2014, is one of 25 in phase 3, and was the 49th registered.
Biogen’s Multiple Sclerosis, Relapsing-Remitting studies by the year they started, since 1999.
None of the studies under way reaches primary completion within a year.
Among the 22 studies testing Dimethyl Fumarate in Multiple Sclerosis, Relapsing-Remitting, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Biogen’s 78 in Multiple Sclerosis, Relapsing-Remitting:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The main objectives of Part 1 are as follows: To evaluate the safety, tolerability, and efficacy of BG00012 in pediatric participants with RRMS, as compared with a disease-modifying treatment and to assess health outcomes and evolution of disability. The primary objective of Part 2 is to evaluate the long-term safety of BG00012 in participants who completed Week 96 in Part 1 of Study 109MS306. The secondary objective of Part 2 is to describe the long-term MS outcomes of BG00012 in participants who completed Week 96 in Part 1 of Study 109MS306.
Key Inclusion Criteria:
Key Exclusion Criteria:
NOTE: Other protocol-defined inclusion/exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive the recommended dose of 240 mg orally, twice a day
Drug: dimethyl fumarate
Participants will receive the recommended dose of 30 μg (weekly)
Drug: Interferon β-1a
administered orally
Also known as: BG00012, Tecfidera
administered by intramuscular injection
Also known as: Avonex
Part 1: Proportion of Participants Free of New or Newly Enlarging T2 Hyperintense Lesions on Brain Magnetic Resonance Imaging (MRI) Scans
Participants who were free of new or newly enlarging T2 hyperintense lesions were assessed on Brain MRI scans.
Time frame: At Week 96
Part 2: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)
An adverse event (AE) was any unfavorable and unintended sign (including an abnormal assessment such as an abnormal laboratory value), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. An SAE was any untoward medical occurrence that at any dose resulted in death, in the view of the Investigator, placed the participant at immediate risk of death, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, resulted in a birth defect. TEAEs were defined as AEs occurring or worsening after beginning study treatment (after the first dose).
Time frame: From Week 96 up to last follow-up visit (up to Week 340)
Part 2: Number of Participants Who Discontinued Study Treatment Due to an AE
An AE was any unfavorable and unintended sign (including an abnormal assessment such as an abnormal laboratory value), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.
Time frame: From Week 96 up to last follow-up visit (up to Week 340)
Part 1: Number of New or Newly Enlarged T2 Hyperintense Lesions on Brain MRI Scans
The number of new or newly enlarging T2 hyperintense lesions that developed in each participant was assessed on Brain MRI scans.
Time frame: At Weeks 24 and Week 96
Part 1: Proportion of Participants Free of New or Newly Enlarging T2 Hyperintense Lesions on Brain MRI Scans
Participants who were free of new or newly enlarging T2 hyperintense lesions were assessed on Brain MRI scans.
Time frame: At Weeks 24 and 48
Part 1: Proportion of Participants Free of New MRI Activity as Measured by Brain MRI Scans
Participants free of Gd-enhancing MRI lesions and new or newly enlarging T2 MRI lesions were assessed on Brain MRI Scans.
Time frame: At Weeks 24, 48, and 96
Part 1: Time to First Relapse
Relapses are defined as new or recurrent neurologic symptoms not associated with fever or infection, lasting at least 24 hours, and accompanied by new objective neurological findings upon examination by the examining neurologist. The time to first relapse was defined as the time from the first dose in Part 1 up to the first relapse. Time to First Relapse was estimated by Kaplan-Meier method.
Time frame: Up to Week 96
Part 1: Proportion of Relapse-Free Participants
Relapses are defined as new or recurrent neurologic symptoms not associated with fever or infection, lasting at least 24 hours, and accompanied by new objective neurological findings upon examination by the examining neurologist. The proportion of relapse-free participants was estimated using the Kaplan-Meier method.
Time frame: Up to Week 96
Part 1: Annualized Relapse Rate (ARR)
ARR is calculated as the total number of relapses that occurred during the study divided by the total number of participant-years. ARR was analyzed using negative binomial regression model.
Time frame: At Weeks 48 and 96
Part 1: Number of Participants With TEAEs and TESAEs
An AE was any unfavorable and unintended sign (including an abnormal assessment such as an abnormal laboratory value), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. An SAE was any untoward medical occurrence that at any dose resulted in death, in the view of the Investigator, placed the participant at immediate risk of death, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, resulted in a birth defect. TEAEs were defined as AEs occurring or worsening after beginning study treatment (after the first dose).
Time frame: From Day 1 up to Week 96
Part 1: Change From Baseline in Vital Signs (Temperature)
Negative change from baseline indicated reduction in temperature.
Time frame: Baseline, Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84 and 96
Part 1: Change From Baseline in Vital Signs (Pulse Rate)
Negative change from baseline indicated reduction in pulse rate.
Time frame: Baseline, Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84 and 96
Part 1: Change From Baseline in Vital Signs (Blood Pressure)
Negative change from baseline indicated reduction in blood pressure.
Time frame: Baseline, Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84 and 96
Part 1: Change From Baseline in Vital Signs (Respiratory Rate)
Negative change from baseline indicated reduction in respiratory rate.
Time frame: Baseline, Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84 and 96
Part 1: Number of Participants With Shifts From Baseline in Electrocardiograms (ECG) Abnormalities
Clinical significance of abnormalities in ECG was determined based on the investigator's discretion. Shift to abnormal indicated values that were normal or unknown at baseline and shifted to abnormal values post-baseline.
Time frame: Up to Week 96
Part 1: Number of Participants With Shifts From Baseline in Clinical Laboratory Parameters (Hematology Parameters)
Hematology parameters included leukocytes, erythrocytes, hemoglobin, hematocrit, platelets, eosinophils, lymphocytes, monocytes and neutrophils. These parameters were flagged as low, normal, or high relative to parameter's normal range or as unknown if no result was available. Here, shift to low indicated values that were normal, high or unknown at baseline and shifted to low values postbaseline. Shift to high indicated values that were normal, low or unknown at baseline and shifted to high postbaseline values. The categories with at least one participant with shift from baseline in these parameters are reported.
Time frame: Baseline up to Week 96
Part 1: Change From Baseline in Coagulation Parameters [Activated Partial Thromboplastin Time (aPTT)]
A negative change from baseline indicated a reduction in aPTT.
Time frame: Baseline, Weeks 24, 48 and 96
Part 1: Change From Baseline in Coagulation Parameters [Prothrombin Time (PT)]
A negative change from baseline indicated a reduction in PT.
Time frame: Baseline, Weeks 24, 48 and 96
Part 1: Change From Baseline in Coagulation Parameters [International Normalized Ratio (INR)]
A negative change from baseline indicated a reduction in clotting time.
Time frame: Baseline, Weeks 24, 48 and 96
Part 1: Number of Participants With Shifts From Baseline in Clinical Laboratory Parameters (Blood Chemistry Parameters)
Parameters included sodium, potassium, chloride, bilirubin, alkaline phosphatase, aspartate aminotransferase, alanine aminotransferase, gamma glutamyl transferase, urea nitrogen, creatinine, bicarbonate, calcium, magnesium, phosphate, urate and glucose. These parameters were flagged as low, normal or high relative to parameter's normal range or as unknown if no result was available, by Investigator. Here, shift to low indicated values that were normal, high or unknown at baseline and shifted to low values postbaseline. Shift to high indicated values that were normal, low or unknown at baseline and shifted to high values postbaseline. Categories with at least one participant with shift from baseline in these parameters are reported.
Time frame: Baseline up to Week 96
Part 1: Number of Participants With Shifts From Baseline in Clinical Laboratory Parameters (Urinalysis Parameters)
Urinalysis included assessments of glucose, ketones, occult blood, protein, specific gravity. These parameters were flagged as low, normal, or high relative to parameter's normal range or as unknown if no result was available, by the Investigator. Here, shift to low indicated values that were normal, high or unknown at baseline and shifted to low values postbaseline. Shift to high indicated values that were normal, low or unknown at baseline and shifted to high postbaseline. The categories with at least one participant with shift from baseline in these parameters are reported.
Time frame: Baseline up to Week 96
Part 1: Fatigue Score Measured by the Pediatric Quality of Life Inventory (PedsQL) Multidimensional Fatigue Scale
The PedsQL multidimensional fatigue questionnaire was answered by the participant (self-assessment) and parent. The fatigue scale contains 18 questions in 3 fatigue dimensions: general fatigue, sleep/rest fatigue and cognitive fatigue. Each item was scored on 5-point Likert scale (0=never to 4=almost always). Each individual score was then reversed (subtracted from 4) and linearly transformed as follows: 0=100, 1=75, 2=50, 3=25, 4=0. For each dimension, total score was calculated as the sum of all the items/number of items answered. A higher total score indicated fewer problems.
Time frame: Up to Week 96
Part 1: Quality of Life (QOL) as Measured by the PedsQL
The PedsQL QOL questionnaire was answered by the participant (self-assessment) and parent. The QoL scale contains 23 questions in 4 dimensions: Physical Functioning, Emotional Fatigue, Social Fatigue and School Fatigue. Each item was scored on 5-point Likert scale (0=never to 4=almost always). Each individual score was then reversed (subtracted from 4) and linearly transformed as follows: 0=100, 1=75, 2=50, 3=25, 4=0. For each dimension, total score was calculated as the sum of all the items/number of items answered. A higher total score indicated better quality of life.
Time frame: Up to Week 96
Part 1: Change From Baseline in the Expanded Disability Status Scale (EDSS) Score
The EDSS measures the disability status of participants with multiple sclerosis on a scale that ranges from 0 to 10. The first levels 1.0 to 4.5 refer to people with a high degree of ambulatory ability and the subsequent levels 5.0 to 9.5 refer to the loss of ambulatory ability. The range of main categories include (0) = normal neurologic exam; to (5) = ambulatory without aid or rest for 200 meters; disability severe enough to impair full daily activities; to (10) = death due to MS with higher scores indicating more disability. A negative change from baseline indicated an improvement in the disability.
Time frame: Baseline, Week 96
Part 2: Annualized Relapse Rate (ARR)
ARR is calculated as the total number of relapses that occurred during the study divided by the total number of participant-years. ARR was analyzed using negative binomial regression model.
Time frame: From Baseline (Week 96) up to Week 336
Part 2: Change From Baseline in the Expanded Disability Status Scale (EDSS) Score
The EDSS measures the disability status of participants with multiple sclerosis on a scale that ranges from 0 to 10. The first levels 1.0 to 4.5 refer to people with a high degree of ambulatory ability and the subsequent levels 5.0 to 9.5 refer to the loss of ambulatory ability. The range of main categories include (0) = normal neurologic exam; to (5) = ambulatory without aid or rest for 200 meters; disability severe enough to impair full daily activities; to (10) = death due to MS. A negative change from baseline indicated an improvement in the disability.
Time frame: Baseline (Week 96), Week 336
Part 2: Change From Baseline in Brief Visuospatial Memory Test - Revised (BVMT-R) Score
BVMT-R is used to assess learning/memory. In this test, six abstract designs are presented for 10 sec. The display is removed from view, and participants render the stimuli via pencil on paper, manual responses. Each design receives from 0 to 2 points, representing accuracy and location. There are three Learning Trials, and the score is reported as the total number of points earned over the trials. Thus, scores range from 0 to 12 per trial; total score range is 0 to 36 for all three trials. Scores were converted to standardized scores using normative data, ranging from 2-86. The lower the score, the more severe the cognitive impairment while higher scores reflect better visuospatial memory.
Time frame: Baseline (Week 96), Weeks 144,192, 240, 288 and 336
Part 2: Change From Baseline in Symbol Digit Modalities Test (SDMT) Score
SDMT is used to assess processing speed. It consists of 9 abstract symbols. Each symbol is paired with a single digit. The participant is provided with a key, showing each symbol digit pair. In addition, the participants are shown several rows of the 9 symbols, which are arranged pseudo-randomly, without the digit. Participants are asked to voice the digit associated with each symbol as rapidly as possible for 90 seconds. The SDMT score ranges from 0 to 110, where higher scores indicate improvement in cognitive functioning and lower scores indicate worsening.
Time frame: Baseline (Week 96), Weeks 144,192, 240, 288 and 336
Part 2: Number of Participants With or Without School Progression
Participants or caregivers were posed the following question: "During the past year, did \[you/the participant\] progress from one \[class/grade-level\] to the next in school?" Responses were recorded as Yes (participant advanced to the next grade) or No (participant did not advance).
Time frame: At Weeks 144, 192, 240, 288 and 336
Part 2: Change From Baseline in Vital Signs (Temperature)
Negative change from baseline indicated reduction in temperature.
Time frame: Baseline (Week 96), Weeks 120,144, 168, 192, 216, 240, 264, 288, 312, 336, and 340
Part 2: Change From Baseline in Vital Signs (Pulse Rate)
Negative change from baseline indicated reduction in pulse rate.
Time frame: Baseline (Week 96), Weeks 120,144, 168, 192, 216, 240, 264, 288, 312, 336, and 340
Part 2: Change From Baseline in Vital Signs (Blood Pressure)
Negative change from baseline indicated reduction in blood pressure.
Time frame: Baseline (Week 96), Weeks 120,144, 168, 192, 216, 240, 264, 288, 312, 336, and 340
Part 2: Change From Baseline in Vital Signs (Respiratory Rate)
Negative change from baseline indicated reduction in respiratory rate.
Time frame: Baseline (Week 96), Weeks 120,144, 168, 192, 216, 240, 264, 288, 312, 336, and 340
Part 2: Number of Participants With Shifts From Baseline in ECG Abnormalities
Clinical significance of abnormalities in ECG was determined based on the investigator's discretion. Shift to abnormal indicated values that were normal or unknown at baseline and shifted to abnormal values post-baseline.
Time frame: From Baseline (Week 96) to Week 336
Part 2: Number of Participants With Shifts From Baseline in Clinical Laboratory Parameters (Hematology Parameters)
Hematology parameters included leukocytes, erythrocytes, hemoglobin, hematocrit, platelets, eosinophils, lymphocytes, monocytes and neutrophils. These parameters were flagged as low, normal, or high relative to parameter's normal range or as unknown if no result was available. Here, shift to low indicated values that were normal, high or unknown at baseline and shifted to low values postbaseline. Shift to high indicated values that were normal, low or unknown at baseline and shifted to high postbaseline values. The categories with at least one participant with shift from baseline in these parameters are reported.
Time frame: Baseline (Week 96) up to Week 340
Part 2: Number of Participants With Shifts From Baseline in Clinical Laboratory Parameters (Blood Chemistry Parameters)
Parameters included potassium, bilirubin, alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase, gamma glutamyl transferase, urea nitrogen, creatinine, bicarbonate, calcium, magnesium, phosphate, urate and glucose. These parameters were flagged as low, normal or high relative to parameter's normal range or as unknown if no result was available, by Investigator. Here, shift to low indicated values that were normal, high or unknown at baseline and shifted to low values postbaseline. Shift to high indicated values that were normal, low or unknown at baseline and shifted to high values postbaseline. Categories with at least one participant with shift from baseline in these parameters are reported.
Time frame: Baseline (Week 96) up to Week 340
Part 2: Number of Participants With Shifts From Baseline in Clinical Laboratory Parameters (Urinalysis Parameters)
Urinalysis included assessments of erythrocytes, leukocytes and specific gravity. These parameters were flagged as low, normal, or high relative to parameter's normal range or as unknown if no result was available, by the Investigator. Here, shift to low indicated values that were normal, high or unknown at baseline and shifted to low values postbaseline. Shift to high indicated values that were normal, low or unknown at baseline and shifted to high postbaseline. The categories with at least one participant with shift from baseline in these parameters are reported.
Time frame: Baseline up to Week 340
Part 2: Change From Baseline in Height
Time frame: Baseline (Week 96), Weeks 120,144, 168, 192, 216, 240, 264, 288, 312, 336, and 340
Part 2: Change From Baseline in Weight
Time frame: Baseline (Week 96), Weeks 120,144, 168, 192, 216, 240, 264, 288, 312, 336, and 340
Part 2: Change From Baseline in Bone Age
Bone age was tested until the participant reached a bone age of 16 years.
Time frame: Baseline (Week 96), Weeks 144, 192 and 240
Part 2: Number of Male Participants by Tanner Stage Assessment
Tanner pubertal staging in males was assessed for testes and scrotum development and pubic hair growth, progressing from stage 1 (prepubertal) to stage 5 (adult). Assessments ended when bone age reached ≥16 years. Testes and scrotum stages were: 1-prepubertal; 2-enlargement of testes, scrotum reddens, texture change; 3-Enlargement of penis, further growth of testes; 4-Increased size of penis with growth in breadth and development of glans; testes and scrotum larger, scrotum skin darker; 5-adult genitalia. Pubic hair stages were: 1-prepubertal; 2-Sparse growth of long, slightly pigmented hair, straight or curled; 3-Darker, coarser and more curled hair, spreading sparsely over junction of pubes; 4-Hair adult in type, but covering smaller area than in adult; no spread to medial surface of thighs; 5-Adult in type and quantity, with horizontal distribution.
Time frame: At Weeks 96, 144, 192, 240, 288 and 336
Part 2: Number of Female Participants by Tanner Stage Assessment
Tanner pubertal staging in females was assessed for breast development and pubic hair growth, progressing from stage 1 (prepubertal) to stage 5 (adult). Assessments ended when bone age reached ≥16 years or the participant was post-menarche. Breast development stages: 1-prepubertal; 2-breast bud stage with elevation of breast and papilla; enlargement of areola, 3-further enlargement of breast and areola; no separation of their contour; 4-areola and papilla form secondary mound above level of breast; 5-mature stage: projection of papilla only, related to recession of areola. Pubic hair stages: 1-prepubertal (can see velus hair similar to abdominal wall); 2-sparse growth of long, slightly pigmented hair, straight or curled, mainly on labia; 3-Darker, coarser and more curled hair, spreading sparsely over junction of pubes; 4-hair adult in type, but covering smaller area than in adult; no spread to medial surface of thighs; 5-adult in type and quantity, with horizontal distribution.
Time frame: At Weeks 96, 144, 192, 240, 288 and 336
Participants took part in the study at multiple investigative sites from 28 August 2014 to 08 July 2025.
| Milestone | Part 1: BG00012 | Part 1: Interferon β-1a | Part 2: BG00012/ BG00012 | Part 2: IFN β-1a/ BG00012 |
|---|---|---|---|---|
| Started | 79 | 77 | 0 | 0 |
| Treated | 78 | 72 | 0 | 0 |
| Completed | 62 | 42 | 0 | 0 |
| Not completed | 17 | 35 | 0 | 0 |
| Withdrew: Randomized not dosed | 1 | 5 | 0 | 0 |
| Withdrew: Adverse event | 5 | 8 | 0 | 0 |
| Withdrew: Consent withdrawn | 4 | 11 | 0 | 0 |
| Withdrew: Investigator decision | 4 | 9 | 0 | 0 |
| Withdrew: Reason not specified | 3 | 2 | 0 | 0 |
| Milestone | Part 1: BG00012 | Part 1: Interferon β-1a | Part 2: BG00012/ BG00012 | Part 2: IFN β-1a/ BG00012 |
|---|---|---|---|---|
| Started | 0 | 0 | 57 | 35 |
| Completed | 0 | 0 | 16 | 20 |
| Not completed | 0 | 0 | 41 | 15 |
| Withdrew: Adverse event | 0 | 0 | 3 | 2 |
| Withdrew: Lost to follow-up | 0 | 0 | 3 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 8 | 5 |
| Withdrew: Physician decision | 0 | 0 | 20 | 6 |
| Withdrew: Reason not specified | 0 | 0 | 7 | 1 |
Participants who were free of new or newly enlarging T2 hyperintense lesions were assessed on Brain MRI scans.
| proportion of participants | Part 1: BG00012 | Part 1: Interferon β-1a |
|---|---|---|
| Part 1: Proportion of Participants Free of New or Newly Enlarging T2 Hyperintense Lesions on Brain Magnetic Resonance Imaging (MRI) Scans | 0.161 (0.080 to 0.277) | 0.049 (0.006 to 0.165) |
An adverse event (AE) was any unfavorable and unintended sign (including an abnormal assessment such as an abnormal laboratory value), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. An SAE was any untoward medical occurrence that at any dose resulted in death, in the view of the Investigator, placed the participant at immediate risk of death, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, resulted in a birth defect. TEAEs were defined as AEs occurring or worsening after beginning study treatment (after the first dose).
| Participants | Part 2: BG00012/ BG00012 | Part 2: IFN β-1a/ BG00012 |
|---|---|---|
| TEAEs | 49 | 31 |
| TESAEs | 8 | 2 |
An AE was any unfavorable and unintended sign (including an abnormal assessment such as an abnormal laboratory value), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.
| Participants | Part 2: BG00012/ BG00012 | Part 2: IFN β-1a/ BG00012 |
|---|---|---|
| Part 2: Number of Participants Who Discontinued Study Treatment Due to an AE | 2 | 1 |
The number of new or newly enlarging T2 hyperintense lesions that developed in each participant was assessed on Brain MRI scans.
| number of lesions | Part 1: BG00012 | Part 1: Interferon β-1a |
|---|---|---|
| Week 24 | 10.0 ± 14.61 | 11.9 ± 20.16 |
| Week 96 | 19.4 ± 35.79 | 32.1 ± 67.16 |
Participants who were free of new or newly enlarging T2 hyperintense lesions were assessed on Brain MRI scans.
| proportion of participants | Part 1: BG00012 | Part 1: Interferon β-1a |
|---|---|---|
| Week 24 | 0.200 (0.116 to 0.308) | 0.141 (0.066 to 0.250) |
| Week 48 | 0.192 (0.109 to 0.301) | 0.088 (0.029 to 0.193) |
Participants free of Gd-enhancing MRI lesions and new or newly enlarging T2 MRI lesions were assessed on Brain MRI Scans.
| proportion of participants | Part 1: BG00012 | Part 1: Interferon β-1a |
|---|---|---|
| Week 24 | 0.200 (0.116 to 0.308) | 0.141 (0.066 to 0.250) |
| Week 48 | 0.178 (0.098 to 0.285) | 0.088 (0.029 to 0.193) |
| Week 96 | 0.145 (0.069 to 0.258) | 0.048 (0.006 to 0.162) |
Relapses are defined as new or recurrent neurologic symptoms not associated with fever or infection, lasting at least 24 hours, and accompanied by new objective neurological findings upon examination by the examining neurologist. The time to first relapse was defined as the time from the first dose in Part 1 up to the first relapse. Time to First Relapse was estimated by Kaplan-Meier method.
| weeks | Part 1: BG00012 | Part 1: Interferon β-1a |
|---|---|---|
| Part 1: Time to First Relapse | NA (48.4 to NA) | NA (30.4 to NA) |
Relapses are defined as new or recurrent neurologic symptoms not associated with fever or infection, lasting at least 24 hours, and accompanied by new objective neurological findings upon examination by the examining neurologist. The proportion of relapse-free participants was estimated using the Kaplan-Meier method.
| proportion of participants | Part 1: BG00012 | Part 1: Interferon β-1a |
|---|---|---|
| 24 Weeks | 0.868 | 0.767 |
| 48 Weeks | 0.761 | 0.704 |
| 72 Weeks | 0.691 | 0.652 |
| 96 Weeks | 0.662 | 0.523 |
ARR is calculated as the total number of relapses that occurred during the study divided by the total number of participant-years. ARR was analyzed using negative binomial regression model.
| relapses per participant-year | Part 1: BG00012 | Part 1: Interferon β-1a |
|---|---|---|
| Week 48 | 0.324 (0.188 to 0.560) | 0.564 (0.342 to 0.931) |
| Week 96 | 0.240 (0.147 to 0.393) | 0.528 (0.333 to 0.836) |
An AE was any unfavorable and unintended sign (including an abnormal assessment such as an abnormal laboratory value), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. An SAE was any untoward medical occurrence that at any dose resulted in death, in the view of the Investigator, placed the participant at immediate risk of death, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, resulted in a birth defect. TEAEs were defined as AEs occurring or worsening after beginning study treatment (after the first dose).
| Participants | Part 1: BG00012 | Part 1: Interferon β-1a |
|---|---|---|
| TEAEs | 74 | 69 |
| TESAEs | 18 | 21 |
Negative change from baseline indicated reduction in temperature.
| degree Celsius | Part 1: BG00012 | Part 1: Interferon β-1a |
|---|---|---|
| Baseline | 36.6 ± 0.37 | 36.5 ± 0.33 |
| Change at Week 4 | 0.0 ± 0.33 | 0.0 ± 0.27 |
| Change at Week 8 | -0.1 ± 0.35 | 0.0 ± 0.35 |
| Change at Week 12 | -0.1 ± 0.36 | 0.0 ± 0.35 |
| Change at Week 24 | 0.0 ± 0.38 | -0.1 ± 0.38 |
| Change at Week 36 | 0.0 ± 0.30 | 0.0 ± 0.35 |
| Change at Week 48 | 0.0 ± 0.39 | 0.0 ± 0.36 |
| Change at Week 60 | 0.0 ± 0.33 | 0.0 ± 0.36 |
| Change at Week 72 | 0.0 ± 0.38 | 0.0 ± 0.41 |
| Change at Week 84 | 0.0 ± 0.37 | 0.0 ± 0.40 |
| Change at Week 96 | 0.0 ± 0.37 | 0.0 ± 0.37 |
Negative change from baseline indicated reduction in pulse rate.
| beats per minute | Part 1: BG00012 | Part 1: Interferon β-1a |
|---|---|---|
| Baseline | 76.2 ± 14.93 | 76.7 ± 10.63 |
| Change at Week 4 | 2.7 ± 11.53 | -1.3 ± 10.91 |
| Change at Week 8 | 1.7 ± 12.17 | 1.1 ± 8.72 |
| Change at Week 12 | 2.2 ± 13.60 | 0.3 ± 11.77 |
| Change at Week 24 | 0.7 ± 12.43 | -1.2 ± 13.19 |
| Change at Week 36 | 0.9 ± 12.93 | 1.9 ± 11.72 |
| Change at Week 48 | 1.0 ± 16.59 | -1.2 ± 12.71 |
| Change at Week 60 | 2.2 ± 12.70 | -1.1 ± 10.99 |
| Change at Week 72 | 0.0 ± 14.17 | 1.3 ± 11.46 |
| Change at Week 84 | 0.8 ± 14.30 | -0.7 ± 12.41 |
| Change at Week 96 | -0.9 ± 13.92 | -2.6 ± 11.86 |
Negative change from baseline indicated reduction in blood pressure.
| millimeters of mercury (mmHg) | Part 1: BG00012 | Part 1: Interferon β-1a |
|---|---|---|
| Baseline: Systolic Blood Pressure (SBP) | 114.2 ± 10.42 | 115.6 ± 10.15 |
| Change at Week 4: SBP | 1.4 ± 9.00 | -0.7 ± 8.89 |
| Change at Week 8: SBP | 2.2 ± 11.07 | -1.3 ± 11.12 |
| Change at Week 12: SBP | 0.8 ± 9.75 | 0.7 ± 10.46 |
| Change at Week 24: SBP | -1.5 ± 10.72 | 1.8 ± 9.46 |
| Change at Week 36: SBP | 1.8 ± 11.03 | 0.3 ± 9.13 |
| Change at Week 48: SBP | 1.3 ± 9.84 | -1.7 ± 8.76 |
| Change at Week 60: SBP | 2.8 ± 10.26 | 1.5 ± 9.88 |
| Change at Week 72: SBP | 1.6 ± 11.30 | 2.0 ± 12.15 |
| Change at Week 84: SBP | 2.2 ± 10.56 | 1.5 ± 8.82 |
| Change at Week 96: SBP | 0.9 ± 12.44 | -0.7 ± 6.36 |
| Baseline: Diastolic Blood Pressure (DBP) | 68.6 ± 9.28 | 71.4 ± 8.67 |
| Change at Week 4: DBP | 0.4 ± 9.53 | -2.2 ± 9.46 |
| Change at Week 8: DBP | -0.1 ± 9.22 | -1.1 ± 8.92 |
| Change at Week 12: DBP | 0.2 ± 9.00 | -1.0 ± 8.64 |
| Change at Week 24: DBP | -0.1 ± 9.64 | -1.0 ± 9.24 |
| Change at Week 36: DBP | -0.5 ± 9.32 | -1.2 ± 8.28 |
| Change at Week 48: DBP | 0.6 ± 8.20 | -2.3 ± 8.59 |
| Change at Week 60: DBP | 1.2 ± 11.16 | 0.6 ± 9.79 |
| Change at Week 72: DBP | 1.3 ± 9.82 | 0.0 ± 10.28 |
| Change at Week 84: DBP | 1.2 ± 9.40 | 0.5 ± 9.86 |
| Change at Week 96: DBP | -0.5 ± 9.99 | -1.5 ± 9.56 |
Negative change from baseline indicated reduction in respiratory rate.
| breaths per minute | Part 1: BG00012 | Part 1: Interferon β-1a |
|---|---|---|
| Baseline | 17.3 ± 2.96 | 18.4 ± 3.02 |
| Change at Week 4 | 0.2 ± 2.49 | -0.3 ± 2.23 |
| Change at Week 8 | 0.3 ± 2.62 | 0.4 ± 6.19 |
| Change at Week 12 | -0.1 ± 2.36 | -0.9 ± 2.91 |
| Change at Week 24 | 0.0 ± 2.89 | -0.5 ± 3.22 |
| Change at Week 36 | 0.2 ± 3.54 | -0.6 ± 2.99 |
| Change at Week 48 | 0.0 ± 3.38 | -0.6 ± 2.86 |
| Change at Week 60 | 0.1 ± 3.35 | 0.0 ± 2.63 |
| Change at Week 72 | -0.2 ± 2.27 | -0.9 ± 3.32 |
| Change at Week 84 | -0.1 ± 2.82 | -0.4 ± 3.54 |
| Change at Week 96 | -0.5 ± 2.74 | -0.8 ± 2.76 |
Clinical significance of abnormalities in ECG was determined based on the investigator's discretion. Shift to abnormal indicated values that were normal or unknown at baseline and shifted to abnormal values post-baseline.
| Participants | Part 1: BG00012 | Part 1: Interferon β-1a |
|---|---|---|
| Shift to Abnormal, not adverse event | 7 | 4 |
| Shift to Abnormal, adverse event | 0 | 0 |
Hematology parameters included leukocytes, erythrocytes, hemoglobin, hematocrit, platelets, eosinophils, lymphocytes, monocytes and neutrophils. These parameters were flagged as low, normal, or high relative to parameter's normal range or as unknown if no result was available. Here, shift to low indicated values that were normal, high or unknown at baseline and shifted to low values postbaseline. Shift to high indicated values that were normal, low or unknown at baseline and shifted to high postbaseline values. The categories with at least one participant with shift from baseline in these parameters are reported.
| Participants | Part 1: BG00012 | Part 1: Interferon β-1a |
|---|---|---|
| Leukocytes: Shift to Low | 30 | 20 |
| Leukocytes: Shift to High | 6 | 5 |
| Erythrocytes: Shift to Low | 17 | 10 |
| Erythrocytes: Shift to High | 1 | 1 |
| Hemoglobin: Shift to Low | 9 | 5 |
| Hemoglobin: Shift to High | 1 | 0 |
| Hematocrit: Shift to Low | 16 | 11 |
| Hematocrit: Shift to High | 0 | 0 |
| Platelets: Shift to Low | 4 | 5 |
| Platelets: Shift to High | 5 | 3 |
| Eosinophils: Shift to Low | 0 | 0 |
| Eosinophils: Shift to High | 24 | 13 |
| Lymphocytes: Shift to Low | 21 | 5 |
| Lymphocytes: Shift to High | 1 | 1 |
| Monocytes: Shift to Low | 23 | 22 |
| Monocytes: Shift to High | 1 | 3 |
| Neutrophils: Shift to Low | 10 | 9 |
| Neutrophils: Shift to High | 9 | 10 |
A negative change from baseline indicated a reduction in aPTT.
| seconds | Part 1: BG00012 | Part 1: Interferon β-1a |
|---|---|---|
| Baseline | 26.12 ± 2.448 | 26.48 ± 2.605 |
| Change at Week 24 | 0.07 ± 2.406 | -0.36 ± 2.901 |
| Change at Week 48 | 0.16 ± 3.064 | -0.53 ± 2.631 |
| Change at Week 96 | -0.38 ± 2.893 | -0.44 ± 2.657 |
A negative change from baseline indicated a reduction in PT.
| seconds | Part 1: BG00012 | Part 1: Interferon β-1a |
|---|---|---|
| Baseline | 11.54 ± 2.379 | 11.52 ± 1.172 |
| Change at Week 24 | -0.04 ± 1.550 | -0.33 ± 1.343 |
| Change at Week 48 | 0.07 ± 3.373 | -0.45 ± 1.243 |
| Change at Week 96 | -0.19 ± 2.694 | -0.19 ± 0.860 |
A negative change from baseline indicated a reduction in clotting time.
| ratio | Part 1: BG00012 | Part 1: Interferon β-1a |
|---|---|---|
| Baseline | 1.08 ± 0.244 | 1.08 ± 0.131 |
| Change at Week 24 | 0.0 ± 0.159 | -0.03 ± 0.153 |
| Change at Week 48 | 0.0 ± 0.341 | -0.05 ± 0.144 |
| Change at Week 96 | -0.01 ± 0.283 | -0.01 ± 0.103 |
Parameters included sodium, potassium, chloride, bilirubin, alkaline phosphatase, aspartate aminotransferase, alanine aminotransferase, gamma glutamyl transferase, urea nitrogen, creatinine, bicarbonate, calcium, magnesium, phosphate, urate and glucose. These parameters were flagged as low, normal or high relative to parameter's normal range or as unknown if no result was available, by Investigator. Here, shift to low indicated values that were normal, high or unknown at baseline and shifted to low values postbaseline. Shift to high indicated values that were normal, low or unknown at baseline and shifted to high values postbaseline. Categories with at least one participant with shift from baseline in these parameters are reported.
| Participants | Part 1: BG00012 | Part 1: Interferon β-1a |
|---|---|---|
| Sodium: Shift to Low | 0 | 0 |
| Sodium: Shift to High | 1 | 2 |
| Potassium: Shift to Low | 1 | 0 |
| Potassium: Shift to High | 4 | 2 |
| Chloride: Shift to Low | 1 | 0 |
| Chloride: Shift to High | 0 | 0 |
| Bilirubin: Shift to Low | 12 | 12 |
| Bilirubin: Shift to High | 5 | 5 |
| Alkaline Phosphatase: Shift to Low | 2 | 1 |
| Alkaline Phosphatase: Shift to High | 5 | 5 |
| Aspartate Aminotransferase: Shift to Low | 4 | 0 |
| Aspartate Aminotransferase: Shift to High | 6 | 6 |
| Alanine Aminotransferase: Shift to Low | 2 | 1 |
| Alanine Aminotransferase: Shift to High | 15 | 13 |
| Gamma Glutamyl Transferase: Shift to Low | 0 | 0 |
| Gamma Glutamyl Transferase: Shift to High | 3 | 5 |
| Urea Nitrogen: Shift to Low | 0 | 0 |
| Urea Nitrogen: Shift to High | 0 | 1 |
| Creatinine: Shift to Low | 5 | 1 |
| Creatinine: Shift to High | 4 | 4 |
| Bicarbonate: Shift to Low | 4 | 0 |
| Bicarbonate: Shift to High | 1 | 0 |
| Calcium: Shift to Low | 0 | 0 |
| Calcium: Shift to High | 18 | 11 |
| Magnesium: Shift to Low | 0 | 1 |
| Magnesium: Shift to High | 33 | 32 |
| Phosphate: Shift to Low | 4 | 4 |
| Phosphate: Shift to High | 4 | 4 |
| Urate: Shift to Low | 3 | 2 |
| Urate: Shift to High | 6 | 1 |
| Glucose: Shift to Low | 19 | 13 |
| Glucose: Shift to High | 24 | 24 |
Urinalysis included assessments of glucose, ketones, occult blood, protein, specific gravity. These parameters were flagged as low, normal, or high relative to parameter's normal range or as unknown if no result was available, by the Investigator. Here, shift to low indicated values that were normal, high or unknown at baseline and shifted to low values postbaseline. Shift to high indicated values that were normal, low or unknown at baseline and shifted to high postbaseline. The categories with at least one participant with shift from baseline in these parameters are reported.
| Participants | Part 1: BG00012 | Part 1: Interferon β-1a |
|---|---|---|
| Glucose: Shift to Low | 0 | 0 |
| Glucose: Shift to High | 2 | 1 |
| Ketones: Shift to Low | 0 | 0 |
| Ketones: Shift to High | 44 | 10 |
| Occult Blood: Shift to Low | 0 | 0 |
| Occult Blood: Shift to High | 32 | 25 |
| Protein: Shift to Low | 0 | 0 |
| Protein: Shift to High | 44 | 39 |
| Specific Gravity: Shift to Low | 0 | 0 |
| Specific Gravity: Shift to High | 4 | 4 |
The PedsQL multidimensional fatigue questionnaire was answered by the participant (self-assessment) and parent. The fatigue scale contains 18 questions in 3 fatigue dimensions: general fatigue, sleep/rest fatigue and cognitive fatigue. Each item was scored on 5-point Likert scale (0=never to 4=almost always). Each individual score was then reversed (subtracted from 4) and linearly transformed as follows: 0=100, 1=75, 2=50, 3=25, 4=0. For each dimension, total score was calculated as the sum of all the items/number of items answered. A higher total score indicated fewer problems.
| score on a scale | Part 1: BG00012 | Part 1: Interferon β-1a |
|---|---|---|
| Participant's Assessment: General Fatigue | 69.2 ± 23.64 | 74.4 ± 19.89 |
| Participant's Assessment: Sleep/Rest Fatigue | 67.0 ± 22.55 | 69.2 ± 20.42 |
| Participant's Assessment: Cognitive Fatigue | 68.1 ± 23.73 | 72.5 ± 23.22 |
| Parent's Assessment: General Fatigue | 71.1 ± 22.59 | 75.3 ± 18.70 |
| Parent's Assessment: Sleep/Rest Fatigue | 71.8 ± 20.77 | 69.8 ± 20.82 |
| Parent's Assessment: Cognitive Fatigue | 71.2 ± 26.93 | 75.0 ± 20.18 |
The PedsQL QOL questionnaire was answered by the participant (self-assessment) and parent. The QoL scale contains 23 questions in 4 dimensions: Physical Functioning, Emotional Fatigue, Social Fatigue and School Fatigue. Each item was scored on 5-point Likert scale (0=never to 4=almost always). Each individual score was then reversed (subtracted from 4) and linearly transformed as follows: 0=100, 1=75, 2=50, 3=25, 4=0. For each dimension, total score was calculated as the sum of all the items/number of items answered. A higher total score indicated better quality of life.
| score on a scale | Part 1: BG00012 | Part 1: Interferon β-1a |
|---|---|---|
| Participant's Assessment: About My Health and Activities | 79.2 ± 19.44 | 83.1 ± 16.39 |
| Participant's Assessment: About My Feelings | 67.5 ± 24.50 | 74.4 ± 21.30 |
| Participant's Assessment: How I get Along With Others | 86.8 ± 17.39 | 93.6 ± 10.25 |
| Participant's Assessment: About Work or School | 68.5 ± 21.18 | 70.7 ± 21.50 |
| Parent's Assessment: Physical Functioning | 78.3 ± 22.07 | 83.1 ± 14.89 |
| Parent's Assessment: Emotional Functioning | 68.1 ± 24.35 | 73.0 ± 23.63 |
| Parent's Assessment: Social Functioning | 86.7 ± 19.92 | 90.7 ± 15.17 |
| Parent's Assessment: Work/Study/School Functioning | 71.3 ± 23.08 | 73.9 ± 17.61 |
The EDSS measures the disability status of participants with multiple sclerosis on a scale that ranges from 0 to 10. The first levels 1.0 to 4.5 refer to people with a high degree of ambulatory ability and the subsequent levels 5.0 to 9.5 refer to the loss of ambulatory ability. The range of main categories include (0) = normal neurologic exam; to (5) = ambulatory without aid or rest for 200 meters; disability severe enough to impair full daily activities; to (10) = death due to MS with higher scores indicating more disability. A negative change from baseline indicated an improvement in the disability.
| score on a scale | Part 1: BG00012 | Part 1: Interferon β-1a |
|---|---|---|
| Baseline | 1.16 ± 1.074 | 1.12 ± 0.966 |
| Change at Week 96 | -0.03 ± 1.045 | 0.13 ± 0.748 |
ARR is calculated as the total number of relapses that occurred during the study divided by the total number of participant-years. ARR was analyzed using negative binomial regression model.
| relapses per participant-year | Part 2: BG00012/ BG00012 | Part 2: IFN β-1a/ BG00012 |
|---|---|---|
| Part 2: Annualized Relapse Rate (ARR) | 0.141 (0.076 to 0.261) | 0.182 (0.093 to 0.356) |
The EDSS measures the disability status of participants with multiple sclerosis on a scale that ranges from 0 to 10. The first levels 1.0 to 4.5 refer to people with a high degree of ambulatory ability and the subsequent levels 5.0 to 9.5 refer to the loss of ambulatory ability. The range of main categories include (0) = normal neurologic exam; to (5) = ambulatory without aid or rest for 200 meters; disability severe enough to impair full daily activities; to (10) = death due to MS. A negative change from baseline indicated an improvement in the disability.
| score on a scale | Part 2: BG00012/ BG00012 | Part 2: IFN β-1a/ BG00012 |
|---|---|---|
| Baseline (Week 96) | 0.95 ± 0.951 | 1.16 ± 0.983 |
| Change at Week 336 | -0.11 ± 0.764 | 0.14 ± 0.808 |
BVMT-R is used to assess learning/memory. In this test, six abstract designs are presented for 10 sec. The display is removed from view, and participants render the stimuli via pencil on paper, manual responses. Each design receives from 0 to 2 points, representing accuracy and location. There are three Learning Trials, and the score is reported as the total number of points earned over the trials. Thus, scores range from 0 to 12 per trial; total score range is 0 to 36 for all three trials. Scores were converted to standardized scores using normative data, ranging from 2-86. The lower the score, the more severe the cognitive impairment while higher scores reflect better visuospatial memory.
| score on a scale | Part 2: BG00012/ BG00012 | Part 2: IFN β-1a/ BG00012 |
|---|---|---|
| Trial 1: Baseline (Week 96) | 7.33 ± 2.545 | 6.50 ± 2.502 |
| Trial 1: Change at Week 144 | -0.33 ± 2.663 | 0.55 ± 2.420 |
| Trial 1: Change at Week 192 | 0.86 ± 2.390 | 0.92 ± 2.216 |
| Trial 1: Change at Week 240 | 0.04 ± 1.837 | 1.78 ± 2.636 |
| Trial 1: Change at Week 288 | 0.95 ± 1.572 | 1.29 ± 2.901 |
| Trial 1: Change at Week 336 | -0.13 ± 2.475 | 1.00 ± 1.886 |
| Trial 2: Baseline (Week 96) | 9.41 ± 2.432 | 8.91 ± 2.441 |
| Trial 2: Change at Week 144 | -0.42 ± 2.572 | 0.00 ± 2.582 |
| Trial 2: Change at Week 192 | 0.89 ± 2.374 | 0.48 ± 2.257 |
| Trial 2: Change at Week 240 | 0.00 ± 2.255 | 0.59 ± 2.024 |
| Trial 2: Change at Week 288 | 0.50 ± 1.277 | 0.48 ± 2.064 |
| Trial 2: Change at Week 336 | -0.27 ± 1.534 | 0.79 ± 1.584 |
| Trial 3: Baseline (Week 96) | 9.98 ± 1.995 | 9.59 ± 2.014 |
| Trial 3: Change at Week 144 | -0.27 ± 2.580 | 0.10 ± 2.166 |
| Trial 3: Change at Week 192 | 0.71 ± 1.655 | 0.36 ± 2.119 |
| Trial 3: Change at Week 240 | 0.24 ± 1.832 | 0.19 ± 2.370 |
| Trial 3: Change at Week 288 | 0.00 ± 2.340 | 0.48 ± 1.914 |
| Trial 3: Change at Week 336 | 0.00 ± 1.558 | 0.37 ± 1.606 |
SDMT is used to assess processing speed. It consists of 9 abstract symbols. Each symbol is paired with a single digit. The participant is provided with a key, showing each symbol digit pair. In addition, the participants are shown several rows of the 9 symbols, which are arranged pseudo-randomly, without the digit. Participants are asked to voice the digit associated with each symbol as rapidly as possible for 90 seconds. The SDMT score ranges from 0 to 110, where higher scores indicate improvement in cognitive functioning and lower scores indicate worsening.
| score on a scale | Part 2: BG00012/ BG00012 | Part 2: IFN β-1a/ BG00012 |
|---|---|---|
| Baseline (Week 96) | 61.34 ± 13.053 | 60.42 ± 11.198 |
| Change at Week 144 | 0.37 ± 8.575 | 4.03 ± 10.108 |
| Change at Week 192 | 2.43 ± 7.530 | 5.60 ± 9.583 |
| Change at Week 240 | 4.54 ± 6.671 | 8.70 ± 10.791 |
| Change at Week 288 | 6.71 ± 13.712 | 9.81 ± 10.172 |
| Change at Week 336 | 5.53 ± 8.383 | 8.89 ± 12.364 |
Participants or caregivers were posed the following question: "During the past year, did \[you/the participant\] progress from one \[class/grade-level\] to the next in school?" Responses were recorded as Yes (participant advanced to the next grade) or No (participant did not advance).
| Participants | Part 2: BG00012/ BG00012 | Part 2: IFN β-1a/ BG00012 |
|---|---|---|
| Week 144 — Yes | 41 | 19 |
| Week 144 — No | 1 | 5 |
| Week 192 — Yes | 27 | 20 |
| Week 192 — No | 1 | 1 |
| Week 240 — Yes | 18 | 17 |
| Week 240 — No | 1 | 1 |
| Week 288 — Yes | 15 | 13 |
| Week 288 — No | 2 | 2 |
| Week 336 — Yes | 35 | 17 |
| Week 336 — No | 5 | 5 |
Negative change from baseline indicated reduction in temperature.
| degree Celsius | Part 2: BG00012/ BG00012 | Part 2: IFN β-1a/ BG00012 |
|---|---|---|
| Baseline (Week 96) | 36.54 ± 0.400 | 36.44 ± 0.243 |
| Change at Week 120 | -0.03 ± 0.401 | 0.07 ± 0.236 |
| Change at Week 144 | -0.04 ± 0.411 | 0.06 ± 0.283 |
| Change at Week 168 | -0.04 ± 0.408 | 0.04 ± 0.280 |
| Change at Week 192 | -0.01 ± 0.462 | -0.03 ± 0.284 |
| Change at Week 216 | 0.00 ± 0.455 | 0.00 ± 0.249 |
| Change at Week 240 | -0.10 ± 0.381 | 0.05 ± 0.242 |
| Change at Week 264 | -0.10 ± 0.359 | -0.01 ± 0.307 |
| Change at Week 288 | -0.16 ± 0.442 | 0.04 ± 0.202 |
| Change at Week 312 | -0.04 ± 0.358 | 0.00 ± 0.344 |
| Change at Week 336 | -0.23 ± 0.581 | -0.02 ± 0.246 |
| Change at Week 340 | -0.09 ± 0.435 | 0.00 ± 0.331 |
Negative change from baseline indicated reduction in pulse rate.
| beats per minute | Part 2: BG00012/ BG00012 | Part 2: IFN β-1a/ BG00012 |
|---|---|---|
| Baseline (Week 96) | 75.1 ± 11.72 | 75.5 ± 12.47 |
| Change at Week 120 | 1.3 ± 12.37 | 3.4 ± 8.99 |
| Change at Week 144 | 0.7 ± 10.67 | 3.1 ± 10.30 |
| Change at Week 168 | -2.7 ± 9.50 | 3.2 ± 12.88 |
| Change at Week 192 | 0.0 ± 11.06 | 3.6 ± 12.23 |
| Change at Week 216 | 6.2 ± 16.04 | 4.0 ± 13.88 |
| Change at Week 240 | 1.2 ± 12.63 | 1.4 ± 10.01 |
| Change at Week 264 | 3.1 ± 13.87 | 0.5 ± 13.34 |
| Change at Week 288 | 2.2 ± 12.91 | -0.1 ± 12.86 |
| Change at Week 312 | 0.7 ± 14.82 | -2.8 ± 12.78 |
| Change at Week 336 | -6.9 ± 14.18 | 0.1 ± 14.02 |
| Change at Week 340 | 1.8 ± 10.81 | -0.9 ± 12.86 |
Negative change from baseline indicated reduction in blood pressure.
| mmHg | Part 2: BG00012/ BG00012 | Part 2: IFN β-1a/ BG00012 |
|---|---|---|
| Baseline (Week 96): SBP | 114.5 ± 10.99 | 114.3 ± 7.83 |
| Change at Week 120: SBP | 0.5 ± 11.05 | 3.2 ± 9.62 |
| Change at Week 144: SBP | 2.1 ± 10.85 | 2.7 ± 11.61 |
| Change at Week 168: SBP | 1.7 ± 11.28 | 5.3 ± 6.65 |
| Change at Week 192: SBP | 1.4 ± 10.22 | 3.1 ± 10.20 |
| Change at Week 216: SBP | 3.9 ± 9.28 | 3.6 ± 9.64 |
| Change at Week 240: SBP | 4.3 ± 11.26 | 3.2 ± 9.81 |
| Change at Week 264: SBP | 5.6 ± 7.35 | 4.5 ± 5.52 |
| Change at Week 288: SBP | 6.6 ± 12.21 | 4.0 ± 8.48 |
| Change at Week 312: SBP | 5.1 ± 11.48 | 1.8 ± 9.17 |
| Change at Week 336: SBP | 4.8 ± 8.91 | 0.8 ± 9.66 |
| Change at Week 340: SBP | 6.5 ± 7.92 | 4.1 ± 8.84 |
| Baseline (Week 96): DBP | 67.8 ± 8.82 | 70.5 ± 8.62 |
| Change at Week 120: DBP | 2.3 ± 8.51 | 2.2 ± 7.22 |
| Change at Week 144: DBP | 1.4 ± 8.51 | 1.9 ± 7.49 |
| Change at Week 168: DBP | 2.9 ± 9.50 | 0.1 ± 8.72 |
| Change at Week 192: DBP | 3.8 ± 9.55 | 0.9 ± 8.29 |
| Change at Week 216: DBP | 5.9 ± 9.91 | 0.1 ± 9.75 |
| Change at Week 240: DBP | 4.9 ± 10.08 | 0.9 ± 7.38 |
| Change at Week 264: DBP | 4.6 ± 8.17 | -0.3 ± 7.26 |
| Change at Week 288: DBP | 3.6 ± 10.81 | 0.7 ± 7.88 |
| Change at Week 312: DBP | 5.6 ± 10.85 | 2.2 ± 8.77 |
| Change at Week 336: DBP | 7.3 ± 9.66 | 0.2 ± 8.94 |
| Change at Week 340: DBP | 5.3 ± 8.39 | 2.3 ± 9.96 |
Negative change from baseline indicated reduction in respiratory rate.
| breaths per minute | Part 2: BG00012/ BG00012 | Part 2: IFN β-1a/ BG00012 |
|---|---|---|
| Baseline (Week 96) | 16.8 ± 2.42 | 16.9 ± 2.55 |
| Change at Week 120 | 0.4 ± 2.76 | 0.5 ± 2.29 |
| Change at Week 144 | 0.3 ± 2.07 | 0.0 ± 2.34 |
| Change at Week 168 | 0.4 ± 2.50 | 0.5 ± 3.10 |
| Change at Week 192 | 0.5 ± 2.74 | 0.7 ± 3.36 |
| Change at Week 216 | -0.2 ± 2.57 | 0.4 ± 2.57 |
| Change at Week 240 | 0.0 ± 1.96 | 0.6 ± 3.00 |
| Change at Week 264 | -0.2 ± 1.88 | -0.1 ± 2.59 |
| Change at Week 288 | -0.1 ± 3.08 | -0.1 ± 2.43 |
| Change at Week 312 | 0.3 ± 2.63 | -0.5 ± 2.42 |
| Change at Week 336 | -1.7 ± 3.04 | 0.4 ± 2.79 |
| Change at Week 340 | -0.4 ± 3.20 | 0.6 ± 2.87 |
Clinical significance of abnormalities in ECG was determined based on the investigator's discretion. Shift to abnormal indicated values that were normal or unknown at baseline and shifted to abnormal values post-baseline.
| Participants | Part 2: BG00012/ BG00012 | Part 2: IFN β-1a/ BG00012 |
|---|---|---|
| Shift to Abnormal, not adverse event | 5 | 1 |
| Shift to Abnormal, adverse event | 0 | 0 |
Hematology parameters included leukocytes, erythrocytes, hemoglobin, hematocrit, platelets, eosinophils, lymphocytes, monocytes and neutrophils. These parameters were flagged as low, normal, or high relative to parameter's normal range or as unknown if no result was available. Here, shift to low indicated values that were normal, high or unknown at baseline and shifted to low values postbaseline. Shift to high indicated values that were normal, low or unknown at baseline and shifted to high postbaseline values. The categories with at least one participant with shift from baseline in these parameters are reported.
| Participants | Part 2: BG00012/ BG00012 | Part 2: IFN β-1a/ BG00012 |
|---|---|---|
| Leukocytes: Shift to Low | 12 | 11 |
| Leukocytes: Shift to High | 4 | 8 |
| Erythrocytes: Shift to Low | 9 | 9 |
| Erythrocytes: Shift to High | 1 | 1 |
| Hemoglobin: Shift to Low | 5 | 4 |
| Hemoglobin: Shift to High | 1 | 0 |
| Hematocrit: Shift to Low | 7 | 5 |
| Hematocrit: Shift to High | 1 | 2 |
| Platelets: Shift to Low | 6 | 4 |
| Platelets: Shift to High | 2 | 0 |
| Eosinophils: Shift to Low | 0 | 0 |
| Eosinophils: Shift to High | 2 | 3 |
| Lymphocytes: Shift to Low | 8 | 11 |
| Lymphocytes: Shift to High | 0 | 0 |
| Monocytes: Shift to Low | 10 | 10 |
| Monocytes: Shift to High | 2 | 2 |
| Neutrophils: Shift to Low | 12 | 4 |
| Neutrophils: Shift to High | 7 | 12 |
Parameters included potassium, bilirubin, alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase, gamma glutamyl transferase, urea nitrogen, creatinine, bicarbonate, calcium, magnesium, phosphate, urate and glucose. These parameters were flagged as low, normal or high relative to parameter's normal range or as unknown if no result was available, by Investigator. Here, shift to low indicated values that were normal, high or unknown at baseline and shifted to low values postbaseline. Shift to high indicated values that were normal, low or unknown at baseline and shifted to high values postbaseline. Categories with at least one participant with shift from baseline in these parameters are reported.
| Participants | Part 2: BG00012/ BG00012 | Part 2: IFN β-1a/ BG00012 |
|---|---|---|
| Potassium: Shift to Low | 0 | 0 |
| Potassium: Shift to High | 3 | 3 |
| Bilirubin: Shift to Low | 4 | 3 |
| Bilirubin: Shift to High | 1 | 4 |
| Alkaline Phosphatase: Shift to Low | 1 | 2 |
| Alkaline Phosphatase: Shift to High | 1 | 2 |
| Alanine Aminotransferase: Shift to Low | 1 | 0 |
| Alanine Aminotransferase: Shift to High | 7 | 9 |
| Aspartate Aminotransferase: Shift to Low | 0 | 0 |
| Aspartate Aminotransferase: Shift to High | 7 | 7 |
| Gamma Glutamyl Transferase: Shift to Low | 5 | 0 |
| Gamma Glutamyl Transferase: Shift to High | 0 | 2 |
| Urea Nitrogen: Shift to Low | 0 | 0 |
| Urea Nitrogen: Shift to High | 0 | 1 |
| Creatinine: Shift to Low | 2 | 2 |
| Creatinine: Shift to High | 0 | 2 |
| Bicarbonate: Shift to Low | 4 | 4 |
| Bicarbonate: Shift to High | 1 | 0 |
| Calcium: Shift to Low | 1 | 0 |
| Calcium: Shift to High | 7 | 6 |
| Magnesium: Shift to Low | 1 | 1 |
| Magnesium: Shift to High | 19 | 6 |
| Phosphate: Shift to Low | 0 | 3 |
| Phosphate: Shift to High | 2 | 5 |
| Urate: Shift to Low | 1 | 2 |
| Urate: Shift to High | 2 | 2 |
| Glucose: Shift to Low | 4 | 2 |
| Glucose: Shift to High | 13 | 16 |
Urinalysis included assessments of erythrocytes, leukocytes and specific gravity. These parameters were flagged as low, normal, or high relative to parameter's normal range or as unknown if no result was available, by the Investigator. Here, shift to low indicated values that were normal, high or unknown at baseline and shifted to low values postbaseline. Shift to high indicated values that were normal, low or unknown at baseline and shifted to high postbaseline. The categories with at least one participant with shift from baseline in these parameters are reported.
| Participants | Part 2: BG00012/ BG00012 | Part 2: IFN β-1a/ BG00012 |
|---|---|---|
| Erythrocytes: Shift to Low | 0 | 0 |
| Erythrocytes: Shift to High | 14 | 11 |
| Leukocytes: Shift to Low | 0 | 0 |
| Leukocytes: Shift to High | 5 | 6 |
| Specific Gravity: Shift to Low | 0 | 0 |
| Specific Gravity: Shift to High | 9 | 8 |
| centimeters (cm) | Part 2: BG00012/ BG00012 | Part 2: IFN β-1a/ BG00012 |
|---|---|---|
| Baseline (Week 96) | 167.5 ± 7.09 | 169.0 ± 9.37 |
| Change at Week 120 | 0.36 ± 1.592 | 0.76 ± 2.878 |
| Change at Week 144 | 0.72 ± 1.916 | 1.67 ± 4.021 |
| Change at Week 168 | 1.13 ± 3.120 | 1.92 ± 4.855 |
| Change at Week 192 | 1.37 ± 3.306 | 2.14 ± 5.407 |
| Change at Week 216 | 1.71 ± 3.604 | 2.47 ± 5.654 |
| Change at Week 240 | 1.85 ± 3.862 | 2.52 ± 5.858 |
| Change at Week 264 | 2.16 ± 4.336 | 2.75 ± 6.661 |
| Change at Week 288 | 2.37 ± 4.777 | 3.09 ± 7.743 |
| Change at Week 312 | 2.29 ± 4.878 | 3.62 ± 8.121 |
| Change at Week 336 | 1.94 ± 4.830 | 3.03 ± 7.019 |
| Change at Week 340 | 3.32 ± 6.691 | 4.17 ± 8.611 |
| kilograms (Kg) | Part 2: BG00012/ BG00012 | Part 2: IFN β-1a/ BG00012 |
|---|---|---|
| Baseline (Week 96) | 67.5 ± 14.67 | 65.1 ± 13.59 |
| Change at Week 120 | 0.45 ± 3.642 | 0.93 ± 2.675 |
| Change at Week 144 | 0.97 ± 3.979 | 2.32 ± 4.692 |
| Change at Week 168 | 1.15 ± 4.322 | 2.54 ± 6.622 |
| Change at Week 192 | 1.27 ± 4.740 | 4.68 ± 8.084 |
| Change at Week 216 | 1.65 ± 5.712 | 5.74 ± 8.983 |
| Change at Week 240 | 0.83 ± 8.684 | 5.90 ± 9.945 |
| Change at Week 264 | 3.73 ± 6.806 | 6.99 ± 11.307 |
| Change at Week 288 | 4.24 ± 7.296 | 7.17 ± 7.584 |
| Change at Week 312 | 4.48 ± 8.116 | 8.04 ± 8.116 |
| Change at Week 336 | 6.35 ± 6.995 | 7.49 ± 8.993 |
| Change at Week 340 | 7.25 ± 7.457 | 8.29 ± 8.310 |
Bone age was tested until the participant reached a bone age of 16 years.
| Years | Part 2: BG00012/ BG00012 | Part 2: IFN β-1a/ BG00012 |
|---|---|---|
| Baseline (Week 96) | 14.46 ± 0.877 | 14.17 ± 0.983 |
| Change at Week 144 | 0.50 ± 0.577 | 0.50 ± 0.707 |
| Change at Week 192 | 2.00 ± 0.000 | 1.50 ± 0.707 |
| Change at Week 240 | — | 2.00 ± NA |
Tanner pubertal staging in males was assessed for testes and scrotum development and pubic hair growth, progressing from stage 1 (prepubertal) to stage 5 (adult). Assessments ended when bone age reached ≥16 years. Testes and scrotum stages were: 1-prepubertal; 2-enlargement of testes, scrotum reddens, texture change; 3-Enlargement of penis, further growth of testes; 4-Increased size of penis with growth in breadth and development of glans; testes and scrotum larger, scrotum skin darker; 5-adult genitalia. Pubic hair stages were: 1-prepubertal; 2-Sparse growth of long, slightly pigmented hair, straight or curled; 3-Darker, coarser and more curled hair, spreading sparsely over junction of pubes; 4-Hair adult in type, but covering smaller area than in adult; no spread to medial surface of thighs; 5-Adult in type and quantity, with horizontal distribution.
| Participants | Part 2: BG00012/ BG00012 | Part 2: IFN β-1a/ BG00012 |
|---|---|---|
| Testes and Scrotum, Week 96, Stage 1 | 0 | 0 |
| Testes and Scrotum, Week 96, Stage 2 | 1 | 1 |
| Testes and Scrotum, Week 96, Stage 3 | 0 | 1 |
| Testes and Scrotum, Week 96, Stage 4 | 4 | 1 |
| Testes and Scrotum, Week 96, Stage 5 | 9 | 3 |
| Pubic hair, Week 96, Stage 1 | 0 | 0 |
| Pubic hair, Week 96, Stage 2 | 1 | 1 |
| Pubic hair, Week 96, Stage 3 | 0 | 1 |
| Pubic hair, Week 96, Stage 4 | 4 | 1 |
| Pubic hair, Week 96, Stage 5 | 9 | 3 |
| Testes and Scrotum, Week 144, Stage 1 | 0 | 0 |
| Testes and Scrotum, Week 144, Stage 2 | 0 | 0 |
| Testes and Scrotum, Week 144, Stage 3 | 1 | 0 |
| Testes and Scrotum, Week 144, Stage 4 | 1 | 2 |
| Testes and Scrotum, Week 144, Stage 5 | 2 | 2 |
| Pubic hair, Week 144, Stage 1 | 0 | 0 |
| Pubic hair, Week 144, Stage 2 | 0 | 0 |
| Pubic hair, Week 144, Stage 3 | 1 | 0 |
| Pubic hair, Week 144, Stage 4 | 1 | 2 |
| Pubic hair, Week 144, Stage 5 | 2 | 2 |
| Testes and Scrotum, Week 192, Stage 1 | 0 | 0 |
| Testes and Scrotum, Week 192, Stage 2 | 0 | 0 |
| Testes and Scrotum, Week 192, Stage 3 | 0 | 0 |
| Testes and Scrotum, Week 192, Stage 4 | 1 | 3 |
| Testes and Scrotum, Week 192, Stage 5 | 3 | 1 |
| Pubic hair, Week 192, Stage 1 | 0 | 0 |
| Pubic hair, Week 192, Stage 2 | 0 | 0 |
| Pubic hair, Week 192, Stage 3 | 0 | 0 |
| Pubic hair, Week 192, Stage 4 | 1 | 3 |
| Pubic hair, Week 192, Stage 5 | 3 | 1 |
| Testes and Scrotum, Week 240, Stage 1 | 0 | 0 |
| Testes and Scrotum, Week 240, Stage 2 | 0 | 0 |
| Testes and Scrotum, Week 240, Stage 3 | 0 | 0 |
| Testes and Scrotum, Week 240, Stage 4 | 0 | 1 |
| Testes and Scrotum, Week 240, Stage 5 | 2 | 2 |
| Pubic hair, Week 240, Stage 1 | 0 | 0 |
| Pubic hair, Week 240, Stage 2 | 0 | 0 |
| Pubic hair, Week 240, Stage 3 | 0 | 0 |
| Pubic hair, Week 240, Stage 4 | 0 | 1 |
| Pubic hair, Week 240, Stage 5 | 2 | 2 |
| Testes and Scrotum, Week 288, Stage 1 | 0 | 0 |
| Testes and Scrotum, Week 288, Stage 2 | 0 | 0 |
| Testes and Scrotum, Week 288, Stage 3 | 0 | 0 |
| Testes and Scrotum, Week 288, Stage 4 | 0 | 0 |
| Testes and Scrotum, Week 288, Stage 5 | 0 | 5 |
| Pubic hair, Week 288, Stage 1 | 0 | 0 |
| Pubic hair, Week 288, Stage 2 | 0 | 0 |
| Pubic hair, Week 288, Stage 3 | 0 | 0 |
| Pubic hair, Week 288, Stage 4 | 0 | 0 |
| Pubic hair, Week 288, Stage 5 | 0 | 5 |
| Testes and Scrotum, Week 336, Stage 1 | 0 | 0 |
| Testes and Scrotum, Week 336, Stage 2 | 0 | 0 |
| Testes and Scrotum, Week 336, Stage 3 | 0 | 0 |
| Testes and Scrotum, Week 336, Stage 4 | 2 | 1 |
| Testes and Scrotum, Week 336, Stage 5 | 1 | 5 |
| Pubic hair, Week 336, Stage 1 | 0 | 0 |
| Pubic hair, Week 336, Stage 2 | 0 | 0 |
| Pubic hair, Week 336, Stage 3 | 0 | 0 |
| Pubic hair, Week 336, Stage 4 | 2 | 1 |
| Pubic hair, Week 336, Stage 5 | 1 | 5 |
Tanner pubertal staging in females was assessed for breast development and pubic hair growth, progressing from stage 1 (prepubertal) to stage 5 (adult). Assessments ended when bone age reached ≥16 years or the participant was post-menarche. Breast development stages: 1-prepubertal; 2-breast bud stage with elevation of breast and papilla; enlargement of areola, 3-further enlargement of breast and areola; no separation of their contour; 4-areola and papilla form secondary mound above level of breast; 5-mature stage: projection of papilla only, related to recession of areola. Pubic hair stages: 1-prepubertal (can see velus hair similar to abdominal wall); 2-sparse growth of long, slightly pigmented hair, straight or curled, mainly on labia; 3-Darker, coarser and more curled hair, spreading sparsely over junction of pubes; 4-hair adult in type, but covering smaller area than in adult; no spread to medial surface of thighs; 5-adult in type and quantity, with horizontal distribution.
| Participants | Part 2: BG00012/ BG00012 | Part 2: IFN β-1a/ BG00012 |
|---|---|---|
| Breasts, Week 96, Stage 1 | 0 | 0 |
| Breasts, Week 96, Stage 2 | 0 | 0 |
| Breasts, Week 96, Stage 3 | 0 | 0 |
| Breasts, Week 96, Stage 4 | 6 | 3 |
| Breasts, Week 96, Stage 5 | 6 | 5 |
| Pubic hair, Week 96, Stage 1 | 0 | 0 |
| Pubic hair, Week 96, Stage 2 | 0 | 0 |
| Pubic hair, Week 96, Stage 3 | 0 | 0 |
| Pubic hair, Week 96, Stage 4 | 6 | 4 |
| Pubic hair, Week 96, Stage 5 | 6 | 4 |
| Breasts, Week 144, Stage 1 | 0 | 0 |
| Breasts, Week 144, Stage 2 | 0 | 0 |
| Breasts, Week 144, Stage 3 | 0 | 0 |
| Breasts, Week 144, Stage 4 | 3 | 0 |
| Breasts, Week 144, Stage 5 | 3 | 2 |
| Pubic hair, Week 144, Stage 1 | 0 | 0 |
| Pubic hair, Week 144, Stage 2 | 0 | 0 |
| Pubic hair, Week 144, Stage 3 | 0 | 0 |
| Pubic hair, Week 144, Stage 4 | 3 | 0 |
| Pubic hair, Week 144, Stage 5 | 3 | 2 |
| Breasts, Week 192, Stage 1 | 0 | 0 |
| Breasts, Week 192, Stage 2 | 0 | 0 |
| Breasts, Week 192, Stage 3 | 0 | 0 |
| Breasts, Week 192, Stage 4 | 0 | 0 |
| Breasts, Week 192, Stage 5 | 1 | 0 |
| Pubic hair, Week 192, Stage 1 | 0 | 0 |
| Pubic hair, Week 192, Stage 2 | 0 | 0 |
| Pubic hair, Week 192, Stage 3 | 0 | 0 |
| Pubic hair, Week 192, Stage 4 | 0 | 0 |
| Pubic hair, Week 192, Stage 5 | 1 | 0 |
| Breasts, Week 240, Stage 1 | 0 | 0 |
| Breasts, Week 240, Stage 2 | 0 | 0 |
| Breasts, Week 240, Stage 3 | 0 | 0 |
| Breasts, Week 240, Stage 4 | 0 | 0 |
| Breasts, Week 240, Stage 5 | 0 | 0 |
| Pubic hair, Week 240, Stage 1 | 0 | 0 |
| Pubic hair, Week 240, Stage 2 | 0 | 0 |
| Pubic hair, Week 240, Stage 3 | 0 | 0 |
| Pubic hair, Week 240, Stage 4 | 0 | 0 |
| Pubic hair, Week 240, Stage 5 | 0 | 0 |
| Breasts, Week 288, Stage 1 | 0 | 0 |
| Breasts, Week 288, Stage 2 | 0 | 0 |
| Breasts, Week 288, Stage 3 | 0 | 0 |
| Breasts, Week 288, Stage 4 | 0 | 0 |
| Breasts, Week 288, Stage 5 | 0 | 0 |
| Pubic hair, Week 288, Stage 1 | 0 | 0 |
| Pubic hair, Week 288, Stage 2 | 0 | 0 |
| Pubic hair, Week 288, Stage 3 | 0 | 0 |
| Pubic hair, Week 288, Stage 4 | 0 | 0 |
| Pubic hair, Week 288, Stage 5 | 0 | 0 |
| Breasts, Week 336, Stage 1 | 0 | 0 |
| Breasts, Week 336, Stage 2 | 0 | 0 |
| Breasts, Week 336, Stage 3 | 0 | 0 |
| Breasts, Week 336, Stage 4 | 0 | 0 |
| Breasts, Week 336, Stage 5 | 1 | 0 |
| Pubic hair, Week 336, Stage 1 | 0 | 0 |
| Pubic hair, Week 336, Stage 2 | 0 | 0 |
| Pubic hair, Week 336, Stage 3 | 0 | 0 |
| Pubic hair, Week 336, Stage 4 | 0 | 0 |
| Pubic hair, Week 336, Stage 5 | 1 | 0 |
Collected over From first dose of study drug up to last follow-up visit (Week 340). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1: BG00012 | 0/78 (0%) | 18/78 (23.1%) | 74/78 (94.9%) |
| Part 1: Interferon β-1a | 0/72 (0%) | 21/72 (29.2%) | 69/72 (95.8%) |
| Part 2: BG00012/ BG00012 | 0/57 (0%) | 8/57 (14%) | 48/57 (84.2%) |
| Part 2: IFN β-1a/ BG00012 | 0/35 (0%) | 2/35 (5.7%) | 31/35 (88.6%) |
| Event | Part 1: BG00012 | Part 1: Interferon β-1a | Part 2: BG00012/ BG00012 | Part 2: IFN β-1a/ BG00012 |
|---|---|---|---|---|
| Multiple sclerosis relapseNervous system disorders | 13/78 | 18/72 | 3/57 | 2/35 |
| Optic neuritisNervous system disorders | 1/78 | 0/72 | 1/57 | 1/35 |
| Congenital cystic kidney diseaseCongenital, familial and genetic disorders | 0/78 | 0/72 | 1/57 | 0/35 |
| Herpes zosterInfections and infestations | 0/78 | 0/72 | 1/57 | 0/35 |
| Joint dislocationInjury, poisoning and procedural complications | 0/78 | 0/72 | 1/57 | 0/35 |
| WoundInjury, poisoning and procedural complications | 0/78 | 0/72 | 1/57 | 0/35 |
| EpilepsyNervous system disorders | 1/78 | 0/72 | 1/57 | 0/35 |
| SyncopeNervous system disorders | 0/78 | 0/72 | 1/57 | 0/35 |
| Abortion missedPregnancy, puerperium and perinatal conditions | 0/78 | 0/72 | 1/57 | 0/35 |
| Borderline personality disorderPsychiatric disorders | 0/78 | 0/72 | 1/57 | 0/35 |
| Event | Part 1: BG00012 | Part 1: Interferon β-1a | Part 2: BG00012/ BG00012 | Part 2: IFN β-1a/ BG00012 |
|---|---|---|---|---|
| Influenza like illnessGeneral disorders | 2/78 | 36/72 | 0/57 | 1/35 |
| Multiple sclerosis relapseNervous system disorders | 23/78 | 23/72 | 15/57 | 16/35 |
| Abdominal painGastrointestinal disorders | 32/78 | 5/72 | 7/57 | 5/35 |
| FlushingVascular disorders | 30/78 | 1/72 | 4/57 | 10/35 |
| HeadacheNervous system disorders | 22/78 | 26/72 | 13/57 | 2/35 |
| PyrexiaGeneral disorders | 8/78 | 17/72 | 10/57 | 4/35 |
| VomitingGastrointestinal disorders | 18/78 | 6/72 | 5/57 | 3/35 |
| NasopharyngitisInfections and infestations | 18/78 | 9/72 | 8/57 | 8/35 |
| Covid-19Infections and infestations | 0/78 | 0/72 | 11/57 | 8/35 |
| ErythemaSkin and subcutaneous tissue disorders | 8/78 | 0/72 | 3/57 | 7/35 |
Intent-to-Treat (ITT) set included all participants who were randomized and received at least one dose of study treatment. Ethnicity data was not collected in this study.
| Age, Continuous(Years) | Part 1: BG00012 | Part 1: Interferon β-1a | Total |
|---|---|---|---|
| Mean | 14.9 ± 1.61 | 15.0 ± 1.64 | 14.9 ± 1.62 |
| Sex: Female, Male(Participants) | Part 1: BG00012 | Part 1: Interferon β-1a | Total |
|---|---|---|---|
| Female | 52 | 49 | 101 |
| Male | 26 | 23 | 49 |
| Race/Ethnicity, Customized(Participants) | Part 1: BG00012 | Part 1: Interferon β-1a | Total |
|---|---|---|---|
| Race — White | 11 | 14 | 25 |
| Race — Asian | 1 | 1 | 2 |
| Race — Not Reported due to Confidentiality Regulations | 27 | 26 | 53 |
| Race — Other | 3 | 0 | 3 |
| Race — Unknown/Missing | 36 | 31 | 67 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/.
Data sharing details ↗ · vivli.org
Ran from Aug 2014 to primary completion in Jul 2025, 130 months.
Results were first posted in May 2026, 10 months after primary completion.
Of 28 industry-sponsored phase 3 interventional studies under Multiple Sclerosis, Relapsing-Remitting, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 65. This study's 130 months is above that.
Counting every sponsor, half of 38 studies reached it within 48 months; a quarter within 27 and three quarters within 66.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dimethyl Fumarate
Multiple Sclerosis, Relapsing-Remitting →